The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer.
Katrin Marie Sjoquist
No relevant relationships to disclose
Michael Friedlander
No relevant relationships to disclose
Linda R. Mileshkin
No relevant relationships to disclose
Michael Quinn
No relevant relationships to disclose
Jeffrey C. Goh
No relevant relationships to disclose
Catherine M. Shannon
No relevant relationships to disclose
David Bowtell
No relevant relationships to disclose
Magdalena Plebanski
No relevant relationships to disclose
Sonia Yip
No relevant relationships to disclose
Kerri Carlton
No relevant relationships to disclose
Kim Gillies
No relevant relationships to disclose
Julie Martyn
No relevant relationships to disclose
Val Gebski
No relevant relationships to disclose